{
    "clinical_study": {
        "@rank": "141257", 
        "acronym": "Implant QOL", 
        "arm_group": [
            {
                "arm_group_label": "LDR boost", 
                "arm_group_type": "Active Comparator", 
                "description": "After completion of 46 Gy of external beam radiotherapy subjects will undergo a permanent seed radioactive implant to the prostate using iodine-125 seeds to deliver a dose of 110 Gy"
            }, 
            {
                "arm_group_label": "HDR boost", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects in this arm will undergo an HDR implant to deliver 15 Gy to the prostate prior to commencing the external beam component of their treatment."
            }
        ], 
        "brief_summary": {
            "textblock": "Optimal non surgical treatment of prostate cancer requires dose escalation which is\n      frequently provided by adding a brachytherapy \"boost\" to a short course of external beam\n      radiotherapy. The hypothesis in this randomized study is that a High Dose Rate (HDR)\n      brachytherapy boost leads to equivalent or better Prostate Specific Antigen (PSA)\n      recurrence-free survival when compared to a Low Dose Rate (LDR) brachytherapy boost and that\n      it is associated with a more favorable toxicity profile and  improved quality of life."
        }, 
        "brief_title": "Improving Quality of Life After Prostate Brachytherapy: a Comparison of HDR and LDR Brachytherapy", 
        "completion_date": {
            "#text": "October 2020", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostate Cancer Upper Tier Intermediate Risk or High Risk", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Upper tier intermediate risk with at least 2 of the following factors\n\n               1. Tumor-Nodes-Metastases Tumor stage 2B or greater\n\n               2. Gleason Score 7\n\n               3. PSA > 10\n\n               4. > 50% of the biopsies positive\n\n          -  OR High risk prostate cancer with one of the following factors\n\n               1. T3a\n\n               2. Gleason Score8-10\n\n               3. PSA >20\n\n          -  Positive prostate biopsy within 6 months (reviewed centrally)\n\n          -  International Prostate Symptom Score < 16\n\n          -  Prostate volume < 60 cc\n\n          -  Negative staging CT and Bone scan within 3 months prior to registration\n\n          -  History and physical examination within 90 days prior to registration\n\n          -  European Cooperative Oncology Group performance status 0-1 prior to registration\n\n          -  Age >45\n\n          -  Patient suitable for procedure under anesthesia\n\n        Exclusion Criteria:\n\n          -  Prior invasive malignancy (except non melanoma skin cancer) unless disease-free for\n             at least 3 years prior to registration\n\n          -  Previous prostatectomy, cryotherapy or High Intensity Focussed Ultrasound for\n             prostate cancer\n\n          -  Previous pelvic irradiation or prostate brachytherapy"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "45 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01936883", 
            "org_study_id": "H13-02139"
        }, 
        "intervention": [
            {
                "arm_group_label": "HDR boost", 
                "description": "High dose rate brachytherapy", 
                "intervention_name": "HDR", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": "LDR boost", 
                "description": "Low dose rate brachytherapy boost", 
                "intervention_name": "LDR", 
                "intervention_type": "Radiation"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "prostatic neoplasm", 
            "brachytherapy", 
            "quality of life", 
            "high dose rate", 
            "low dose rate"
        ], 
        "lastchanged_date": "September 5, 2013", 
        "location": {
            "contact": {
                "email": "fbachand@bccancer.bc.ca", 
                "last_name": "Francois Bachand, MD", 
                "phone": "250 979 6645"
            }, 
            "contact_backup": {
                "email": "jcrook@bccancer.bc.ca", 
                "last_name": "Juanita Crook, MD", 
                "phone": "250 979 6645"
            }, 
            "facility": {
                "address": {
                    "city": "Kelowna", 
                    "country": "Canada", 
                    "state": "British Columbia", 
                    "zip": "V1Y5L3"
                }, 
                "name": "British Columbia Cancer Agency Center for the Southern Interior"
            }, 
            "investigator": [
                {
                    "last_name": "Ross Halperin, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Matt Schmidt, MSc", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Deidre Batchelar, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Cynthia Araujo, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "David Kim, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "David Petrik, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Jim Rose, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Marie-Pierre Millette, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Michelle Hilts, PhD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "official_title": "IMPROVING QUALITY OF LIFE AFTER OPTIMAL RADIOTHERAPY FOR INTERMEDIATE AND HIGH RISK PROSTATE CANCER: A Randomized Comparison of HDR Versus LDR BRACHYTHERAPY BOOST", 
        "other_outcome": {
            "description": "regular PSA monitoring every 6 months to 3 years and then annually to determine PSA recurrence free survival", 
            "measure": "Efficacy", 
            "safety_issue": "No", 
            "time_frame": "8 years"
        }, 
        "overall_contact": {
            "email": "fbachand@bccancer.bc.ca", 
            "last_name": "Francois Bachand, MD", 
            "phone": "250 979 6645"
        }, 
        "overall_contact_backup": {
            "email": "jcrook@bccancer.bc.ca", 
            "last_name": "Juanita M Crook, MD", 
            "phone": "250 979 6645"
        }, 
        "overall_official": [
            {
                "affiliation": "British Columbia Cancer Agency", 
                "last_name": "Francois Bachand, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "British Columbia Cancer Agency", 
                "last_name": "Juanita Crook, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Canada: Ethics Review Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Quality of life will be measured through validated instruments including International Prostate Symptom Score, the International Index of Erectile Function, and the urinary, bowel and sexual domains of EPIC", 
            "measure": "Quality of Life", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "reference": [
            {
                "PMID": "18963537", 
                "citation": "Bachand F, Martin AG, Beaulieu L, Harel F, Vigneault E. An eight-year experience of HDR brachytherapy boost for localized prostate cancer: biopsy and PSA outcome. Int J Radiat Oncol Biol Phys. 2009 Mar 1;73(3):679-84. doi: 10.1016/j.ijrobp.2008.05.003. Epub 2008 Oct 27."
            }, 
            {
                "PMID": "22513104", 
                "citation": "Schmid M, Crook JM, Batchelar D, Araujo C, Petrik D, Kim D, Halperin R. A phantom study to assess accuracy of needle identification in real-time planning of ultrasound-guided high-dose-rate prostate implants. Brachytherapy. 2013 Jan-Feb;12(1):56-64. doi: 10.1016/j.brachy.2012.03.002. Epub 2012 Apr 17. PubMed PMID: 22513104."
            }, 
            {
                "PMID": "20708853", 
                "citation": "Morton GC, Loblaw DA, Chung H, Tsang G, Sankreacha R, Deabreu A, Zhang L, Mamedov A, Cheung P, Batchelar D, Danjoux C, Szumacher E. Health-related quality of life after single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2011 Aug 1;80(5):1299-305. doi: 10.1016/j.ijrobp.2010.04.046. Epub 2010 Aug 12."
            }, 
            {
                "PMID": "19748692", 
                "citation": "Pieters BR, de Back DZ, Koning CC, Zwinderman AH. Comparison of three radiotherapy modalities on biochemical control and overall survival for the treatment of prostate cancer: a systematic review. Radiother Oncol. 2009 Nov;93(2):168-73. Epub 2009 Sep 11. Review."
            }, 
            {
                "PMID": "20685176", 
                "citation": "Deutsch I, Zelefsky MJ, Zhang Z, Mo Q, Zaider M, Cohen G, Cahlon O, Yamada Y. Comparison of PSA relapse-free survival in patients treated with ultra-high-dose IMRT versus combination HDR brachytherapy and IMRT. Brachytherapy. 2010 Oct-Dec;9(4):313-8. Epub 2010 Aug 4."
            }, 
            {
                "PMID": "16242258", 
                "citation": "Stock RG, Stone NN, Cesaretti JA, Rosenstein BS. Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsy results. Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):527-33. Epub 2005 Oct 19."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01936883"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Quality of Life will be assessed to 3 years using the validated instruments International Prostate Symptom Score, International Index Erectile Function and EPIC", 
            "measure": "Quality of Life long term", 
            "safety_issue": "No", 
            "time_frame": "3 years"
        }, 
        "source": "British Columbia Cancer Agency", 
        "sponsors": {
            "collaborator": {
                "agency": "BC Cancer Foundation", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "British Columbia Cancer Agency", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}